| Date Filed | Type | Description |
| 10/11/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/10/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/10/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 10/10/2023 |
8-K
| Quarterly results |
| 10/04/2023 |
4
| Szalay Aladar (10% Owner) has filed a Form 4 on GENELUX Corp|
Txns:
| Sold 75,690 shares
@ $25.4885, valued at
$1.9M
|
|
| 10/04/2023 |
4
| Jewett Caroline (Head of Quality) has filed a Form 4 on GENELUX Corp|
Txns:
| Granted 22,000 options to buy
@ $24.75, valued at
$544.5k
|
|
| 09/29/2023 |
4
| Szalay Aladar (10% Owner) has filed a Form 4 on GENELUX Corp|
Txns:
| Sold 11,257 shares
@ $24.47, valued at
$275.5k
Sold 2,289 shares
@ $24.12, valued at
$55.2k
|
|
| 09/27/2023 |
4
| Szalay Aladar (10% Owner) has filed a Form 4 on GENELUX Corp|
Txns:
| Sold 3,947 shares
@ $24.82, valued at
$98k
Sold 5,511 shares
@ $25.75, valued at
$141.9k
Sold 1,900 shares
@ $26.6, valued at
$50.5k
Sold 1,100 shares
@ $27.81, valued at
$30.6k
Sold 7,465 shares
@ $22.47, valued at
$167.7k
Sold 12,740 shares
@ $24.03, valued at
$306.1k
Sold 9,600 shares
@ $24.51, valued at
$235.3k
|
|
| 09/27/2023 |
4
| Yu Yong (VP, Clinical Trial Operations) has filed a Form 4 on GENELUX Corp|
Txns:
| Sold 1,883 shares
@ $22.5397, valued at
$42.4k
Sold 1,114 shares
@ $23.5145, valued at
$26.2k
Sold 2,203 shares
@ $24.4623, valued at
$53.9k
Exercised 5,200 options to buy
@ $6, valued at
$31.2k
|
|
| 09/26/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/24/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 08/22/2023 |
4
| Jewett Caroline (Head of Quality) has filed a Form 4 on GENELUX Corp|
Txns:
| Sold 515 shares
@ $23.73, valued at
$12.2k
|
|
| 08/22/2023 |
4
| Smalling Ralph (Head of Regulatory) has filed a Form 4 on GENELUX Corp|
Txns:
| Sold 935 shares
@ $23.73, valued at
$22.2k
|
|
| 08/22/2023 |
4
| Samuelson Doug (CFO) has filed a Form 4 on GENELUX Corp|
Txns:
| Sold 1,297 shares
@ $23.73, valued at
$30.8k
|
|
| 08/22/2023 |
4
| Ryder Sean (General Counsel) has filed a Form 4 on GENELUX Corp|
Txns:
| Sold 328 shares
@ $23.73, valued at
$7.8k
|
|
| 08/22/2023 |
4
| Cappello Joseph (VP, Pharmaceutical Development) has filed a Form 4 on GENELUX Corp|
Txns:
| Sold 3,265 shares
@ $23.73, valued at
$77.5k
|
|
| 08/22/2023 |
4
| Yu Yong (VP, Clinical Trial Operations) has filed a Form 4 on GENELUX Corp|
Txns:
| Sold 3,265 shares
@ $23.73, valued at
$77.5k
|
|
| 08/22/2023 |
4
| Zindrick Thomas (President and CEO) has filed a Form 4 on GENELUX Corp|
Txns:
| Sold 8,349 shares
@ $23.73, valued at
$198.1k
|
|
| 08/21/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/18/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/18/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/18/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/18/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/15/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/09/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/08/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/20/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 07/20/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 07/20/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 07/18/2023 |
8-K
| Quarterly results |
| 07/14/2023 |
8-K
| Quarterly results |
| 07/05/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 07/03/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
|